阿联酋结束了毒品垄断,要求每个药品都有多种药剂,以促进竞争和供应稳定。 UAE ends drug monopolies, requiring multiple agents per medicine to boost competition and supply stability.

阿联酋根据《2026年2月24日联邦法令》,从2026年2月24日起,通过要求制药公司为每种药物指定多个授权代理人,结束了对医疗产品的垄断。 The UAE has ended monopolies on medical products by requiring pharmaceutical companies to appoint multiple authorized agents for each drug, effective February 24, 2026, under Federal Decree-Law No. 2024年的38张 38 of 2024. 阿联酋药品机构引入了这一规则,以促进竞争,提高供应链的复原力,确保持续的药品供应,并加强对公共卫生紧急情况的应对。 The Emirates Drug Establishment (EDE) introduced the rule to boost competition, improve supply chain resilience, ensure continuous medicine availability, and enhance response to public health emergencies. 此举旨在降低药物价格,加强分销效率,支持国家卫生安全。 The move aims to lower drug prices, strengthen distribution efficiency, and support national health security. 它还支持阿联酋成为全球制药创新和制造业中心的目标。 It also supports the UAE’s goal of becoming a global hub for pharmaceutical innovation and manufacturing.